Cardiac remodeling in obese patients after laparoscopic sleeve gastrectomy

World J Surg. 2013 Mar;37(3):565-72. doi: 10.1007/s00268-012-1874-8.

Abstract

Background: Obesity is associated with high morbidity and represents an increasing health care problem worldwide. Laparoscopic sleeve gastrectomy (LSG) has been used effectively for weight loss and co-morbidity remission. In this retrospective study, we evaluated cardiac reverse remodeling at medium-term follow-up by echocardiography, the amount of cardiovascular medications, and the impact of co-morbidities after sleeve gastrectomy.

Methods: Altogether, 16 obese patients (4 men, 12 women; 46.4 ± 10.3 years) underwent complete clinical evaluation, laboratory tests, and color Doppler/tissue Doppler imaging echocardiography preoperatively and 12-20 months after bariatric surgery.

Results: Body weight (mean body mass index) was significantly reduced (from 44.8 ± 8.0 to 31.2 ± 7.8 kg/m2; p = 0.001). Lipid profile significantly improved: total cholesterol and triglycerides decreased (respectively: 215.5 ± 53.8 vs. 205.3 ± 46.6 mg/dl and 184.9 ± 109.3 vs. 116.1 ± 49.9 mg/dl, both p ≤ 0.05), and high-density lipoprotein increased (43.1 ± 10.9 vs. 51.4 ± 12.8 mg/dl, p = 0.005). Systolic blood pressure significantly decreased (from 133.0 ± 17.1 to 120.6 ± 13.7 mmHg; p = 0.04). Diabetes remission was complete in five of six patients (83%) and sleep apnea in four of five (80 %). Echocardiography showed significantly reduced interventricular septum and posterior wall thickness (11.3 ± 1.8 to 9.4 ± 2.1 mm and 10.4 ± 1.7 to 8.6 ± 1.9 mm, respectively; both p < 0.007) and reduced left ventricular mass (absolute value and indexed by height, respectively: 222.41 ± 78.2 to 172.75 ± 66.3 g (p = 0.003) and 55.9 ± 14.3 to 43.8 ± 17.2 g/m(2.7) (p = 0.0004). Antihypertensive drug intake was significantly reduced (p = 0.03), as shown by the 10-year Framingham Risk Score (from 14.2 ± 9.3 to 8.3 ± 9.5%, p = 0.003).

Conclusions: Sleeve gastrectomy is associated with marked improvement in terms of weight loss, lipid profile, type 2 diabetes, sleep apnea, hypertension, and left ventricular hypertrophy, with a significantly reduced Framingham Risk Score.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Bariatric Surgery / adverse effects
  • Bariatric Surgery / methods
  • Body Mass Index
  • Cohort Studies
  • Diabetes Mellitus / physiopathology
  • Diabetes Mellitus / prevention & control
  • Echocardiography, Doppler
  • Female
  • Follow-Up Studies
  • Gastrectomy / adverse effects
  • Gastrectomy / methods*
  • Humans
  • Hypertension / physiopathology
  • Hypertension / prevention & control
  • Laparoscopy / adverse effects
  • Laparoscopy / methods*
  • Lipoproteins, HDL / analysis
  • Lipoproteins, HDL / metabolism
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Obesity, Morbid / diagnosis
  • Obesity, Morbid / surgery*
  • Quality of Life*
  • Retrospective Studies
  • Risk Assessment
  • Treatment Outcome
  • Ventricular Remodeling / physiology*
  • Weight Loss
  • Young Adult

Substances

  • Lipoproteins, HDL